Search for: [Abstract = "Introduction. Dual antiplatelet therapy lasting 12 months is currently recommended for all patients with acute coronary syndrome. As life expectancy increases, the number of patients in advanced age with acute coronary syndromes and comorbidities with high thrombo\-embolic risk \(such as atrial fibrillation, venous thrombotic disease, valvular diseases\) is also increasing. That is why the need for simultaneous administration of dual antiplatelet and oral anticoagulant therapy \(triple therapy\) has become more common recently. Because of the lack of large randomized trials regarding triple therapy, the scale of the problem in Poland is unknown. Aims. To assess the number of patients requiring oral anticoagulation among those hospitalized with acute coronary syndrome in everyday medical practice, to define the reasons of not administering such therapy and to assess the presence of cardiovascular risk factors, prognostic risk factors of bleeding and in\-hospital complications in these patients. Methods. Retrospective analysis included 2279 patients diagnosed with acute coronary syndrome who were admitted to the Departments of Cardiology in Cracow in 2008. Patients were divided into three subgroups depending on the treatment\: 1\/ with prescribed triple therapy\; 2\/ with recommendation of usage of ASA, derivative of thienopyridine and oral anticoagulant\; 3\/ treated with other combinations"]

Number of results: 1